2022
DOI: 10.1016/j.bcp.2022.115108
|View full text |Cite
|
Sign up to set email alerts
|

Cardiovascular risk factors and molecular routes underlying endothelial dysfunction: Novel opportunities for primary prevention

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
5

Citation Types

0
48
0

Year Published

2022
2022
2024
2024

Publication Types

Select...
8
1

Relationship

0
9

Authors

Journals

citations
Cited by 48 publications
(48 citation statements)
references
References 159 publications
0
48
0
Order By: Relevance
“…Endothelial dysfunction, the impaired endothelium-dependent dilation of blood vessels, is considered to be both a cardiovascular disease marker and a pathogenetic factor contributing to the development and progression of cardio- and cerebrovascular disease, including stroke [ 34 , 35 ]. Endothelial dysfunction is caused by impaired basal and stimulated release and activity of nitric oxide (NO) that functions as a powerful vasodilator, an inhibitor of platelet and leukocyte aggregation, and an anti-inflammatory agent [ 36 ]. The contribution of endothelial NO to both maintenance of basal CBF and endothelial-dependent vascular reactivity is traditionally evaluated in both in vivo and in vitro experiments as the dilatory response to Ach, a physiologic stimulator of NO release [ 36 , 37 ].…”
Section: Discussionmentioning
confidence: 99%
See 1 more Smart Citation
“…Endothelial dysfunction, the impaired endothelium-dependent dilation of blood vessels, is considered to be both a cardiovascular disease marker and a pathogenetic factor contributing to the development and progression of cardio- and cerebrovascular disease, including stroke [ 34 , 35 ]. Endothelial dysfunction is caused by impaired basal and stimulated release and activity of nitric oxide (NO) that functions as a powerful vasodilator, an inhibitor of platelet and leukocyte aggregation, and an anti-inflammatory agent [ 36 ]. The contribution of endothelial NO to both maintenance of basal CBF and endothelial-dependent vascular reactivity is traditionally evaluated in both in vivo and in vitro experiments as the dilatory response to Ach, a physiologic stimulator of NO release [ 36 , 37 ].…”
Section: Discussionmentioning
confidence: 99%
“…Endothelial dysfunction is caused by impaired basal and stimulated release and activity of nitric oxide (NO) that functions as a powerful vasodilator, an inhibitor of platelet and leukocyte aggregation, and an anti-inflammatory agent [ 36 ]. The contribution of endothelial NO to both maintenance of basal CBF and endothelial-dependent vascular reactivity is traditionally evaluated in both in vivo and in vitro experiments as the dilatory response to Ach, a physiologic stimulator of NO release [ 36 , 37 ]. Importantly, in PSs rats, the endothelial dysfunction was evident as an inverse response to Ach, while in PSr rats, there was no significant response to Ach.…”
Section: Discussionmentioning
confidence: 99%
“…This decision was made after extensive consideration and reflects the variability in the literature and outcomes associated with different models of disease risk. While there is evidence that vasoconstrictor responses to an exogenous challenge can be impacted by chronic disease risk conditions ( Stapleton et al, 2008 ; Lemaster et al, 2017b ), it is far from a consensus opinion and can be extremely model-dependent, especially when compared to the monumental amount of previous evidence demonstrating the impairment to dilator reactivity in both the cerebral and skeletal muscle circulations that are well correlated with outcome risk severity ( Stapleton et al, 2008 ; Benincasa et al, 2022 ; Zhang, 2022 ).…”
Section: Discussionmentioning
confidence: 99%
“…Since previous FMD studies have reported differences regarding their adherence to key methodological issues, we have overcome this problem by means of a well-defined analysis protocol [ 18 ]. FMD is reduced in subjects with atherosclerosis and cardiovascular risk factors—smokers [ 19 ], subjects with high cholesterol levels [ 20 ], arterial hypertension [ 21 ], diabetes [ 22 ], obesity, aging [ 23 ], and renal failure [ 24 ]. Endothelial dysfunction measured by the FMD of the brachial artery has already been proven in patients with PAPS and SLE [ 25 , 26 ].…”
Section: Discussionmentioning
confidence: 99%